NYSE:JNJPharmaceuticals
Johnson And Johnson Data For IMAAVY Adds To Autoimmune Upside Story
Johnson & Johnson (NYSE:JNJ) released full Phase 2/3 data for IMAAVY (nipocalimab) in warm autoimmune hemolytic anemia, showing durable hemoglobin improvement and reduced steroid use.
The results mark the first clear efficacy signal in this rare, life threatening condition, which currently has no approved therapies.
The program has FDA Priority Review, signaling potential near term regulatory action and heightened attention from clinicians and investors.
For investors watching Johnson &...